$372.69
+4.28
(+1.16%)
As of Oct 15, 2026, 12:54 AM EDT
Price history
Roper Technologies (ROP) is trading up at $372.69 (+1.16%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Information Technology sector.
Roper Technologies revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.79B | $4.61B | $5.19B | $4.73B | $4.02B | $4.83B | $5.37B | $6.18B | $7.04B | $7.90B |
| Growth (year over year) | +5.8% | +21.6% | +12.7% | −8.9% | −14.9% | +20.2% | +11.1% | +15.0% | +13.9% | +12.3% |
| Gross profit | $2.33B | $2.86B | $3.28B | $3.14B | $2.83B | $3.41B | $3.75B | $4.31B | $4.88B | $5.47B |
| Gross margin | 61.5% | 62.2% | 63.2% | 66.4% | 70.3% | 70.5% | 69.9% | 69.7% | 69.3% | 69.2% |
| Operating income | $1.05B | $1.21B | $1.40B | $1.33B | $1.08B | $1.24B | $1.52B | $1.75B | $2.00B | $2.24B |
| Operating margin | 27.8% | 26.3% | 26.9% | 28.1% | 26.9% | 25.7% | 28.4% | 28.2% | 28.4% | 28.3% |
| Net income | $658.6M | $971.8M | $944.4M | $1.77B | $949.7M | $1.15B | $4.54B | $1.38B | $1.55B | $1.54B |
| Net margin | 17.4% | 21.1% | 18.2% | 37.4% | 23.6% | 23.8% | 84.6% | 22.4% | 22.0% | 19.4% |
| EPS (diluted) | $6.43 | $9.39 | $9.05 | $16.82 | $8.98 | $10.82 | $42.55 | $12.89 | $14.35 | $14.20 |
| Balance sheet | ||||||||||
| Cash and equivalents | $757.2M | $671.3M | $364.4M | $709.7M | $308.3M | $351.5M | $792.8M | $214.3M | $188.2M | $297.4M |
| Total assets | $14.3B | $14.3B | $15.2B | $18.1B | $24.0B | $23.7B | $27.0B | $28.2B | $31.3B | $34.6B |
| Total liabilities | $8.54B | $7.45B | $7.51B | $8.62B | $13.5B | $12.2B | $10.9B | $10.7B | $12.5B | $14.7B |
| Long-term debt | $5.81B | $4.35B | $4.94B | $4.67B | $9.06B | $7.12B | $5.96B | $5.83B | $6.58B | $8.60B |
| Shareholders' equity | $5.79B | $6.86B | $7.74B | $9.49B | $10.5B | $11.6B | $16.0B | $17.4B | $18.9B | $19.9B |
| Cash flow | ||||||||||
| Operating cash flow | $963.8M | $1.23B | $1.43B | $1.46B | $1.53B | $2.01B | $734.6M | $2.04B | $2.39B | $2.54B |
| Capital expenditure | $37.3M | $48.8M | $49.1M | — | — | — | — | — | — | — |
| Free cash flow | $926.5M | $1.19B | $1.38B | — | — | — | — | — | — | — |
| Dividends paid | $121.1M | $142.8M | $170.1M | $191.7M | $214.1M | $236.4M | $262.3M | $290.2M | $321.9M | $355.0M |
| Share buybacks | — | — | — | — | — | — | — | $0 | $0 | $500.0M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.76B | $1.88B | $1.88B | $1.94B | $2.02B | $2.06B | $2.10B | $2.11B |
| Growth (year over year) | +12.9% | +16.3% | +12.0% | +13.2% | +14.3% | +9.7% | +11.3% | +8.5% |
| Gross profit | $1.22B | $1.28B | $1.29B | $1.35B | $1.40B | $1.43B | $1.45B | $1.47B |
| Gross margin | 69.2% | 68.3% | 68.7% | 69.2% | 69.5% | 69.5% | 69.4% | 69.7% |
| Operating income | $496.6M | $524.7M | $525.8M | $548.3M | $573.0M | $588.3M | $569.6M | $584.7M |
| Operating margin | 28.1% | 28.0% | 27.9% | 28.2% | 28.4% | 28.6% | 27.2% | 27.7% |
| Net income | $367.9M | $462.3M | $331.1M | $378.3M | $398.5M | $428.4M | $508.9M | $1.17B |
| Net margin | 20.8% | 24.6% | 17.6% | 19.5% | 19.8% | 20.8% | 24.3% | 55.4% |
| EPS (diluted) | $3.40 | $4.29 | $3.06 | $3.49 | $3.68 | $3.97 | $4.87 | $11.62 |
| Balance sheet | ||||||||
| Cash and equivalents | $269.6M | $188.2M | $372.8M | $242.4M | $320.0M | $297.4M | $382.9M | $364.9M |
| Total assets | $31.6B | $31.3B | $31.4B | $33.2B | $34.6B | $34.6B | $34.6B | $35.2B |
| Total liabilities | $13.0B | $12.5B | $12.2B | $13.6B | $14.6B | $14.7B | $15.7B | $16.5B |
| Long-term debt | $7.68B | $6.58B | $6.46B | $7.86B | $9.15B | $8.60B | $9.75B | $10.6B |
| Shareholders' equity | $18.5B | $18.9B | $19.2B | $19.6B | $20.0B | $19.9B | $18.8B | $18.7B |
| Cash flow | ||||||||
| Operating cash flow | $755.4M | $722.2M | $528.7M | $404.1M | $869.5M | $738.0M | $592.1M | $469.5M |
| Dividends paid | $80.5M | $80.8M | $88.6M | $88.6M | $88.8M | $89.0M | $97.4M | $94.0M |
| Share buybacks | — | — | $0 | $0 | — | — | $1.50B | $1.23B |
From Roper Technologies's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Roper Technologies
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
Source: Wikipedia — Roper Technologies
- Headquarters
- Sarasota, Florida From SEC filings, Oct 2026
Recent News (20)
-
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss Basel, 10 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham …
-
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab an…
-
Abhijit Dubey joins Roper Technologies Board of Directors SARASOTA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that Abhijit Dubey has joined the Company's Board of Directors.
-
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular ag…
-
-
-
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) Basel, 23 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen i…
-
-
-
-
-
-
-
Roper Technologies at Citi’s 2026 Global TMT Conference: ai and m&a
Roper Technologies at Citi’s 2026 Global TMT Conference: ai and m&a
-
-
Roper Technologies at Goldman Sachs conference: ai and deal discipline
Roper Technologies at Goldman Sachs conference: ai and deal discipline
-
Roper Technologies In Rebound and a Hot Buy Despite Insider Selling
Roper Technologies In Rebound and a Hot Buy Despite Insider Selling
-
-
Is Roper Technologies Stock Underperforming the Dow?
Is Roper Technologies Stock Underperforming the Dow?
-
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD) Basel, 28 August 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-ret…
More Information Technology stocks
- PLTR Palantir Technologies
- PTC PTC Inc.
- Q Qnity Electronics
- QCOM Qualcomm
- SHOP Shopify
- SMCI Supermicro
- SNDK Sandisk
- SNPS Synopsys